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n	 IntroductIon
Fibromyalgia (FM) is a complex syn-drome which, in Italy, affects at least 
2% of the adult population (1). It is charac-
terized by widespread chronic pain, often 
associated with other symptoms such as 
fatigue, disturbed sleep patterns, functional 
limitations and cognitive impairment (2, 3). 
The presence of these symptoms and any 
comorbidity (4) significantly compromises 
the quality of life of FM patients (5-8). De-
fining the impact of symptoms on patients 
with FM can be a useful tool to evaluate pa-
tient activity and and social function, and 
response to treatment in research and daily 
clinical practice (9-14).
The group of experts in fibromyalgia of the 
OMERACT (Outcome Measures in Rheu-
matology) group, using working party and 
the Delphi methods, has recently exam-
ined the possibility of patients identifying 
principle clinical domains to be used as an 
evaluation tool in clinical trials (2, 15). Be-
ginning with an initial list of 40 potential 
domains, the experts gave marks in terms 
of importance of each domain. In the same 
way, a similar selection was made by dif-
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SUMMARY
Objective: Fibromyalgia (FM) is a complex syndrome that, in Italy, affects at least 2% of the adult population. 
It is characterized by chronic widespread musculoskeletal pain often accompanied by multiple other symptoms. 
The aim of this study was to identify a set of clinical domains for FM considered relevant by both clinicians and 
patients using a consensus process.
Methods: Consensus was achieved using the Delphi method based on questionnaires and systematic, controlled 
opinion feedback. The Delphi exercise involved a panel of 252 rheumatologists and 86 patients with FM as 
defined by the American College of Rheumatology criteria. All of the patients and clinicians were asked to rank 
the relative different domains of FM in order of priority. The content validity index (CVI) was used to establish 
the percentage agreement. The importance of each item was ranked on a 0-3 Likert scale. The frequency, mean 
relevance scores, and frequency importance product were also calculated.
Results: The Delphi exercise showed that the domains ranked highest by patients were similar to those of the 
clinicians, with the exception of tender point intensity (considered relevant by the clinicians but not by the 
patients) and environmental sensitivity (considered important by the patients but not by the clinicians). A final 
8-item model was developed which was considered to demonstrate adequate validity. 
Conclusions: The Delphi exercises identified and ranked relevant key clinical domains that need to be assessed 
in FM research. On the basis of these results, a new patient-reported composite outcome index can be developed 
and used in clinical trials.
Key words: fibromyalgia, Delphi method, pain scales, health-related quality of life, patient-reported outcomes.
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ferent groups of patients with FM from 
different centers. The results from both the 
groups of experts and of patients were the 
same. The list of principal domains select-
ed included: pain, overall state of health, 
fatigue, quality of life (QoL), multidimen-
sional function, sleep pattern and depres-
sion. The so-called secondary domains 
included physical function, tender points, 
cognitive impairment, (lack of concentra-
tion, disorganized thoughts, etc.) and anxi-
ety (15). This working method allowed us 
to sustain construct validity of the potential 
domains, while feasibility and the selec-
tive ability of the specific instruments to be 
used in its application were the subject of a 
separate systematic randomized controlled 
trial (RCT) (12, 16).
Use of the so-called patient reported out-
comes (PRO) is the most accepted method 
of evaluating disease status, especially in 
conditions characterized by chronic pain 
(17, 18). This method is highly appropri-
ate for use in FM (10) given that most of 
the clinical domains considered essential 
for evaluation of the disease, and defined 
as such by the experts of the OMERACT 
group (2, 15, 19) and of the Food and Drug 
Administration (FDA) (20), are patient 
centered.
In line with methods used by the OMER-
ACT group (15, 20), this study was carried 
out using the Delphi method, and involved 
252 rheumatologists and 86 patients with 
FM. The principle aim of the study was to 
reach a unanimous consensus on the list of 
health domains considered to be high prior-
ity both in a research context and in daily 
clinical practice, and considered to be use-
ful for disease evaluation. 
n	 MaterIals and Methods 
Expert working parties 
The items were generated in two succes-
sive phases. First, we carried out a litera-
ture review of clinical studies in FM in 
order to identify the principle outcome 
measures used. Clinical trials published up 
to September 2010 were downloaded from 
the internet using MEDLINE, CINAHL 
and EMBASE search engines. A strategy 
of specific research was developed for each 
database using Cochrane filter for RCT and 
including articles published in English and 
in Italian between 1990 and 2009. The key 
words used were: “Fibromyalgia”, “Chron-
ic pain syndrome”, “Widespread pain”, 
“State of Health”, “Multidisciplinary”, 
“Patient care team”, “Treatment of fibro-
myalgia” or “Management of fibomyalgia” 
and “Trial”. 
The search strategy produced 2,055 ar-
ticles, of which 204 were selected on the 
basis of titles, summaries and key words, 
from which a total of 39 papers were sub-
sequently selected. The list of items was 
re-examined for importance of content by 
a multidisciplinary task force of experts 
in FM: 25 rheumatologists, 4 orthopedic 
surgeons, 3 neurologists, 3 algologists, 2 
psychologists, 6 physiotherapists and 3 oc-
cupational therapists. Each doctor was in-
vited to decide which specific method they 
considered most appropriate to measure 
each clinical domain and to mark each item 
selected according to feasibility. In order 
to reduce the number of clinical domains, 
items were excluded from the list if:
a) they were related to gender;
b) they required use of special equipment;
c) they used terminology which was am-
biguous or difficult to understand;
d) they presented alternatives to other 
items, duplicated them and/or were 
similar to them. The final list was made 
up of a pool of 58 symptoms/domains 
(see Appendix).
Final item selection
The number of items was reduced in order 
to avoid symptoms and/domains which 
were superfluous or repetetive. This was 
achieved by keeping 8-10 symptoms/do-
mains considered to be the most important 
and representative of patients’ general state 
of health. In the next phase, 252 rheuma-
tologists, randomly selected from the list 
of 1,200 members of the Società Italiana di 
Reumatologia (Italian Society of Rheuma-
tology) were interviewed through the inter-
net (http://www.reumatologia.it). 
Each rheumatologist was invited to make 
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their own independent selection, without 
any assistance, of the symptoms/domains 
they considered to be the most important 
and representative from the list of 58 symp-
toms/domains which had been identified by 
the task force. Response was 70.4% (252 
of 538 contacted) representing a third of all 
rheumatologists interviewed. The content 
validity index (CVI) was used to establish 
the proportion/percentage of agreement be-
tween the experts. Lynn (21) recommended 
using a relevance evaluation scale for each 
item providing ordinal level data based 
on the Likert scale from 0 to 4 (4=highly 
relevant, extremely important; 3=very rel-
evant, very important; 2=not very relevant, 
not very important; 1=not relevant, unim-
portant). Once scoring was completed, the 
CVI only included elements with a mark of 
3 or 4, while all descriptors with a mark of 
1 and 2 were not considered. The CVI for-
mula was: CVI or percentage of agreement 
= the number of experts in agreement on 
items receiving scores of 3 or 4 divided by 
the total number of experts. The items were 
considered to have adequate content valid-
ity when agreement was 70% or over, and 
to be questionable or unacceptable when 
agreement among experts was 60-70% or 
less than 60%, respectively. 
Patient working parties
The aim of this phase of the study was 
to reach unanimous agreement, in terms 
of priority and importance of the clinical 
domains, among patients diagnosed with 
FM according to the criteria of the Ameri-
can College of Rheumatology (ACR) (22). 
Rheumatologists involved in the study 
excluded diagnoses other than FM. Other 
exclusion criteria were: comorbidities such 
as to impede full participation in study 
procedures (terminal stage, such as, for ex-
ample, advanced stage renal disease, car-
diac insufficiency or neoplasms), alcohol 
abuse, significant cognitive impairment, 
or psychiatric symptoms which could have 
compromised efficient completion of the 
questionnaire. 
After obtaining local ethics committee ap-
proval for the study, a group of 86 patients 
with FM were invited to take part and gave 
their signed informed consent. These pa-
tients were from three different rheumatol-
ogy centers: the centers of northern, central 
and southern Italy. The patient group was 
considered to provide an adequate repre-
sentative sample of the disease in terms of 
heterogeneity of the symptoms presented 
at the moment of inclusion in the study. 
A rheumatologist experienced in develop-
ing measurement strategies presented each 
patient with the list of the 42 domains that 
were considered to be the most important 
in relation to FM. During the interview, 
each patient was asked to put the various 
domains in the order of priority (mean im-
portance, MI) giving each one a score on 
the Likert scale from 1 to 3 (1=not relevant, 
not important; 2=not very relevant, not 
very important; 3=very relevant, very im-
portant). Mean values were then calculated 
for each item which had obtained a score of 
2. Analysis considered frequency of each 
symptom, and the prevalence and domains 
which satisfied 60% or over of prevalence 
criteria. The frequency importance product 
(FIP) was, therefore, generated for each 
Table I - Domains classified according to importance by clinicians.
Domain Frequency Mean importance
(MI)
Frequency importance 
product (FIP)
1. Pain 79.0 2.85 225.2
2. Fatigue 78.6 2.65 208.3
3. Disturbed sleep patterns 74.6 2.70 201.4
4. Health-related quality of life (HrQl) 73.8 2.60 191.9
5. Depression 70.2 2.60 182.5
6. anxiety 71.8 2.50 179.5
7. Memory lapse and lack of concentration 69.1 2.40 165.8
8. tender points 60.2 2.20 126.4
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item, multiplying the frequency by the MI 
assigned to each domain. For example, the 
FIP relating to the domain pain, estimated 
by clinicians to be the most frequent and 
with the highest range, was 225.2 (FIP pain 
= frequency 79% x MI 2.85 = 225.2) (Table 
I). The FIP represented, therefore, a com-
posite, two-dimensional measurement par-
ticularly useful in establishing the extent of 
importance of a symptom or domain. 
n	 results 
Use of the Delphi method among clini-
cians
Using the Delphi method, 252 rheumatolo-
gists evaluated the importance of each item. 
The items considered important (pain, 
tiredness, disturbed sleep patterns, qual-
ity of life, physical function, depression, 
cognitive impairment, anxiety and tender 
points) which reached a 60.2-79.0% agree-
ment among clinicians were included in the 
final list. Table I shows the frequency, rele-
vance and FIP of each item. Clinicians con-
sidered pain (FIP = 225.5), tiredness (FIP 
= 208.3), disturbed sleep patterns (FIP = 
201.4) and quality of life (FIP = 191.9) to 
be the most important items. 
Use of the Delphi method among patients
The study included 86 patients: 70 women 
and 16 men, mean age 43.9 years, range 
22-68 years, female:male ratio 5:1, com-
parable and similar to other studies in the 
literature. The largest proportion of pa-
tients (58%) had been diagnosed with FM 
1-4 years before the study began. Seventy-
one percent of patients reported the onset 
of symptoms to have been over five years 
before, 35% did not work because of the 
disease, while 42% classified their state 
of health as “poor”. Their level of educa-
tion was generally low: 60.1% had only 
received primary school education (6-11 
years of age) and only 19.9% had gone to 
upper secondary school (14-19 years of 
age). Most patients (77.9%) were married 
and lived with their family while 34% were 
housewives. Forty-one of the 86 subjects 
(52.6%) reported one or more comorbid-
ity, in particular, cardiovascular disease 
(29.2%), and respiratory (14.1%) and met-
abolic (10.5%) problems.
Overall, classification of the domains se-
lected by patients was the same as that 
proposed by the clinicians. Pain was the 
most important symptom (FIP = 282.2), 
while patients considered tiredness, dis-
turbance of sleep pattern, overall state of 
health, quality of life, depression, anxiety 
and cognitive impairment (memory lapse 
and lack of concentration) to be equally 
important. Tender points were considered 
to be important by clinicians but not by 
patients. On the other hand, excessive sen-
sitivity to external stimuli (sounds, lights, 
Tabella II - Domains classified according to importance by patients. 
Domain Items Frequency Mean 
importance
(MI)
Frequency 
importance product 
(FIP)
1. Pain Pain or physical distress; painful joints; pain on palpation 97.3 2.9 282.2
2. Fatigue tiredness; low energy levels 93.6 2.7 252.7
3. Quality of sleep Difficulty in sleeping; insomnia; frequent waking during the 
night
90.1 2.6 234.3
4. Multidimensional 
function 
Difficulting in moving around, in walking or doing physical 
exercises; problems in carrying out daily routine activities, 
work and study, and impact on daily routine
89.8 2.6 233.5
5. Depression Feeling sad, unmotivated, pessimistic, isolated, listless 81.5 2.4 195.6
6. Sensitivity to 
external stimuli 
Sensitivity to sounds, light, smells and/or the cold 78.3 2.4 187.9
7. anxiety Feeling frustrated, worried, scared 76.1 2.3 175.0
8. cognitive 
impairment 
Memory lapse or difficulties in remembering things; loss of 
memory; lack of concentration
74.7 2.1 156.9
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smells) were considered to be important 
by patients but not by clinicians. Patients 
did not take into consideration the domain 
health-related quality of life while the 
rheumatologists did. In spite of this, the 
impact of the disease on physical function 
was, however, considered to be important. 
In particular, reference was made to diffi-
culty in moving around, walking or doing 
physical exercises, problems in carrying 
out daily routine activities, work and study, 
and the impact of the disease on daily life. 
The 8 items reached a prevalence of at least 
70%, while the mean importance (MI) of 
marks given varied between 2.1 (cognitive 
impairment) and 2.9 (pain). The FIP of the 
8 items was between 156.9 and 282.2. Cli-
nicians summarized the last domain as cog-
nitive impairment while patients described 
it in different terms such as, for example, 
“losing attention”, “lack of concentra-
tion”, “memory lapse” and “disorganized 
thoughts”. The domains with the highest 
marks are shown in Table II. 
n	 dIscussIon
In their definition of the classification of 
the 8 items considered to be important dur-
ing the course of FM, a high percentage of 
doctors and patients generally gave pain, 
tiredness and disturbed sleep patterns the 
highest marks of importance. (23) This, 
therefore, confirms the importance of 
these domains, and suggests they should 
be included in evaluation criteria for this 
disease (19). It is interesting to note that 
these items represent the three domains 
which make up the “Fibromialgia Activity 
Score (FAS)” (24) self-evaluation scale, 
and as such are in agreement with recom-
mendations proposed by the OMERACT 
group of experts in FM, the “Syndrome 
Workshop” (15, 19) and the IMMPACT 
(Initiative on Methods, Measurements and 
Pain Assessment in Clinical Trial) group 
(25). The other five domains selected by 
clinicians, including depression and anxi-
ety, state of health-quality of life, memory 
lapse and lack of concentration, and ten-
der points, are generally considered to be 
important also by patients (15, 19). How-
ever, with respect to clinicians, patients 
also consider excessive sensitivity to ex-
ternal stimuli to be important. The most 
important functional items, which were 
underlined by the patients, include ef-
fects of the disease on personal day to day 
planning, achieving routine objectives and 
completing daily tasks, even though they 
did not usually consider health-related 
state of health to be important. According 
to the OMERACT group of experts (15, 
19). clinicians should consider health-re-
lated quality of life to be very important 
in order to adequately evaluate the much 
wider multidimensional aspect of function 
rather than simply physical function. It is 
interesting to note that while rigidity was 
considered to be an important domain by 
the OMERACT group of experts (2,.15, 
19). by systematic revision (12,26) and in 
investigations conducted via internet (27). 
this was not among the domains selected 
by patients who took part in the study, who 
did not consider it to be important. In con-
trast, it is not surprising that pain was the 
domain selected most, often being the first 
symptom reported by the patient. However, 
even though it was classified in first place 
as an indicator of disease severity, pain is 
considered the principle criterion by 79% 
of the doctors interviewed. It should also 
be noted that an objective clinical evalu-
ation made through investigation into ten-
der points was reported by only 60.2% of 
clinicians and that all other criteria select-
ed are to be considered “patient-centered”. 
The variety of criteria available for FM, 
and the lack of a unanimous consensus 
agreement, underlines the need to validate 
an adequate means to measure disease se-
verity. A recent study (8) which involved 
788 patients with FM, defined pain and 
tiredness to be the most important symp-
toms in 54% of participants and to be the 
most characteristic signs of disease, while 
fatigue was chosen as the most important 
item by 28% of those interviewed. Tired-
ness, a common symptom among patients 
with FM (2, 15, 27) which often represents 
one of the most worrying problems, is a 
subjective experience which is described 
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as “extreme and persistent mental and/or 
physical weakness or tiredness”. In spite of 
the fact that the causes of tiredness are lit-
tle known, it has been increasingly used in 
recent years as a measurement of outcome 
in clinical studies (28). Since there is still 
no theoretical model, it remains difficult to 
define tiredness in FM. Along with pain 
and tiredness, disturbed sleep patterns is 
constantly referred to as important by pa-
tients and doctors (27, 29-33). These play 
a primary role in the disease course. Esti-
mates of percentage of patients with FM 
affected by disturbed sleep patterns vary 
from 74 to 95-99% (34). It has also been 
shown that disturbed sleep patterns have a 
significant impact on amplifying pain and 
on the consequent negative impact on func-
tion and psychological-emotional well-be-
ing (32-34). It is not surprising, therefore, 
that both patients and clinicians underline 
the importance of improving the quality of 
sleep, together with treating pain. 
Given the multidimensional characteristic 
of FM and the reported validity and useful-
ness of PRO in evaluating and monitoring 
these patients, we have recently developed 
the fibromyalgia assessment status (FAS) 
questionnaire which combines self-evalu-
ation of the degree of tiredness and pain, 
and quality of sleep (on the basis of sites 
listed in the self-assessment pain scale, 
SAPS) into a single measurement, with 
scores ranging from 0 to 10 (23). This in-
dex includes the first 3 items considered 
to be important by both clinicians and pa-
tients, and can be used to evaluate disease 
severity and define response to treatment. 
In conclusion, this study using the Delphi 
method of evaluation has shown that the 
domains considered to be the most impor-
tant by patients are similar to those indicat-
ed by clinicians, with the exception of ten-
der points (which were not considered to 
be important by patients). The final model 
of 8 items was shown to be have adequate 
construct validity. 
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Appendix
Domains presented in the Delphi study
1. low back pain
2. irritable bowel syndrome 
3. restless leg syndrome 
4. tinnitus
5. cognitive impairment
6. Morning rigidity
7. Fatigue
8. Widespread chronic pain
9. tender point 
10. Multidimensional function
11. Memory lapse
12. tingling extremities
13. constipation
14. Dysmenorrhea 
15. Sjogren’s syndrome
16. raynaud’s phenonemon 
17. Physical weakness
18. Widespread paresthesias
19. temporomandibular joint dysfunction
20. losing attention or lack of concentration (e.g. difficulties in 
concentrating and following train of thought, “fibro-fog”)
21. Difficulty in moving around, walking or doing physical exercises 
22. Unable to do physical exercise
23. Depression (e.g. dissatisfaction, sadness, resignation or self-
effacement, unmotivated) 
24. Unmotivated 
25. Disorganized thoughts (difficulty in expressing oneself, in prompt 
verbal response or in making personal programs and plans)
26. numbness or tingling in the fingers and toes
27. cephalea or migraine
28. Sensitivity to environmental factors (e.g. smells, sounds, lights, 
changes in temperature) 
29. Skin sensitivity
30. involuntary movement
31. Vertigo
32. impact on sleep (e.g. difficulty in falling asleep, insomnia, frequent 
waking during the night)
33. limiting/compromising normal daily routine activities
34. impact on social life (e.g. less time for hobbies or free time, 
problems in traveling) 
35. Problems taking medication (e.g. side effects or intolerance) 
36. impact on family life (e.g. relationship problems with partner or 
children)
37. impact on work/study
38. lack of or low sex drive
39. economic impact (e.g.. cost of medication, health insurance)
40. Problems driving (e.g. pain or fatigue or memory lapse) 
41. anger or irritability
42. Frustration (e.g. due to function limitations, due to social 
relationships) 
43. anxiety (e.g. nervousness)
44. Panic attacks
45. chest pain
46. abdominal pain or cramps
47. Urinary incontinence
48. Strangury, dysuria, difficulties in urinating
49. Shortness of breath
50. Weight loss (<10 kg)
51. loss of appetite
52. loss of smell, taste or flavor
53. Difficulties in urinating
54. gynecological problems (women) 
55. Muscle pain, pain or cramps
56. cold hands
57. Swollen hands
58. Swelling of other joints
